Hippocampal-sparing radiation for lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of hippocampal-sparing prophylactic cranial irradiation (PCI) in patients with pathologically nodal positive non-small-cell lung cancer (NSCLC) who have undergone aggressive treatment. The aim is to reduce the incidence of brain metastasis while minimizing neurocognitive decline associated with traditional whole brain radiotherapy. Participants will receive targeted radiation therapy designed to protect the hippocampus, which is crucial for memory function. The study will assess neurobehavioral outcomes and cognitive functions in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of NSCLC
* Must be adult patients (≥ 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis
* Platinum-based chemotherapy is mandatory
* Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) \> 70 %
* Should have sufficient proficiency in Mandarin language

Exclusion Criteria:

* Have received prior cranial irradiation
* Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ)
* Radiographic evidence of brain metastasis/metastases
* Clinical evidence of extracranial metastatic disease
* Hypersensitivity to magnetic resonance (MR) contrast enhancer
* Serious medical or psychiatric illness

Where it's running

• Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting

Study contacts

• Principal investigator: Chi-Cheng Yang, Ph.D. — Chang Gung University
• Study coordinator: Chi-Cheng Yang, Ph.D.
• Email: ccyang@mail.cgu.edu.tw
• Phone: 886-988378478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response

  Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.

  Recruiting at 20 sites Hellenic Cooperative Oncology Group · Limassol and 19 other locations · NCT07900581

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• What causes vulnerability in older adults with serious diseases and how it affects care decisions

  This study tests how often vulnerability factors appear in older adults with serious illnesses and how these factors influence treatment timing, survival, and quality of life.

  Recruiting Tampere University Hospital · Tampere · NCT07740239

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.